218 related articles for article (PubMed ID: 20630084)
1. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
[TBL] [Abstract][Full Text] [Related]
2. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Lee JM; Sarosy GA; Annunziata CM; Azad N; Minasian L; Kotz H; Squires J; Houston N; Kohn EC
Br J Cancer; 2010 Feb; 102(3):495-9. PubMed ID: 20051952
[TBL] [Abstract][Full Text] [Related]
4. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
5. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
[TBL] [Abstract][Full Text] [Related]
8. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
10. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Chu D; Lacouture ME; Fillos T; Wu S
Acta Oncol; 2008; 47(2):176-86. PubMed ID: 18210295
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
[No Abstract] [Full Text] [Related]
12. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
Manchen E; Robert C; Porta C
J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
[TBL] [Abstract][Full Text] [Related]
13. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
14. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
18. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
